A Conformation Variant of p53 Combined with Machine Learning Identifies Alzheimer Disease in Preclinical and Prodromal Stages
Open accessThe DOI matches its Crossref record; 16 of the 16 references it cites were found in a registry or an index.
Abstract
Early diagnosis of Alzheimer’s disease (AD) is a crucial starting point in disease management. Blood-based biomarkers could represent a considerable advantage in providing AD-risk information in primary care settings. Here, we report new data for a relatively unknown blood-based biomarker that holds promise for AD diagnosis. We evaluate a p53-misfolding conformation recognized by the antibody 2D3A8, also named Unfolded p53 (U-p532D3A8+), in 375 plasma samples derived from InveCe.Ab and PharmaCog/E-ADNI longitudinal studies. A machine learning approach is used to combine U-p532D3A8+ plasma levels with Mini-Mental State Examination (MMSE) and apolipoprotein E epsilon-4 (APOEε4) and is able to predict AD likelihood risk in InveCe.Ab with an overall 86.67% agreement with clinical diagnosis. These algorithms also accurately classify (AUC = 0.92) Aβ+—amnestic Mild Cognitive Impairment (aMCI) patients who will develop AD in PharmaCog/E-ADNI, where subjects were stratified according to Cerebrospinal fluid (CSF) AD markers (Aβ42 and p-Tau). Results support U-p532D3A8+ plasma level as a promising additional candidate blood-based biomarker for AD.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
NIA‐AA Research Framework: Toward a biological definition of Alzheimer's disease
Jack, C. R., Bennett, D. A., Blennow, K., Carrillo, M. C., Dunn, B., Haeberlein, S. B., Holtzman, D. M., Jagust, W., Jessen, F., Karlawish, J., et al. (2018) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2018.02.018 · Cited by 10,537
High performance plasma amyloid-β biomarkers for Alzheimer's disease
Nakamura, A., Kaneko, N., Villemagne, V. L., Kato, T., Doecke, J., Doré, V., Fowler, C., Li, Q.-X., Martins, R., Rowe, C., et al. (2018) · Nature · doi:10.1038/nature25456 · Cited by 1,681
Phase 3 Trials of Solanezumab for Mild-to-Moderate Alzheimer's Disease
Doody, R. S., Thomas, R. G., Farlow, M., Iwatsubo, T., Vellas, B., Joffe, S., Kieburtz, K., Raman, R., Sun, X., Aisen, P. S., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1312889 · Cited by 1,668
CSF Biomarkers and Incipient Alzheimer Disease in Patients With Mild Cognitive Impairment
Mattsson, N. (2009) · JAMA · doi:10.1001/jama.2009.1064 · Cited by 1,176
Regulation of autophagy by cytoplasmic p53
Tasdemir, E., Maiuri, M. C., Galluzzi, L., Vitale, I., Djavaheri-Mergny, M., D'Amelio, M., Criollo, A., Morselli, E., Zhu, C., Harper, F., et al. (2008) · Nature Cell Biology · doi:10.1038/ncb1730 · Cited by 1,132
High-precision plasma β-amyloid 42/40 predicts current and future brain amyloidosis
Schindler, S. E., Bollinger, J. G., Ovod, V., Mawuenyega, K. G., Li, Y., Gordon, B. A., Holtzman, D. M., Morris, J. C., Benzinger, T. L. S., Xiong, C., et al. (2019) · Neurology · doi:10.1212/wnl.0000000000008081 · Cited by 885 · cited 1×
“Correspondingly, U-p532D3A8+ levels could be complementary to other AD biomarkers, such as CSF or plasma Aß [10,49] and therefore could be included in a panel of plasma biomarkers, supporting a personalized AD diagnosis.”
BackgroundA systemic view of Alzheimer disease — insights from amyloid-β metabolism beyond the brain
Wang, J., Gu, B. J., Masters, C. L., & Wang, Y.-J. (2017) · Nature Reviews Neurology · doi:10.1038/nrneurol.2017.111 · Cited by 808
Blood-based biomarkers for Alzheimer disease: mapping the road to the clinic
Hampel, H., O’Bryant, S. E., Molinuevo, J. L., Zetterberg, H., Masters, C. L., Lista, S., Kiddle, S. J., Batrla, R., & Blennow, K. (2018) · Nature Reviews Neurology · doi:10.1038/s41582-018-0079-7 · Cited by 716 · cited 5×
“ccording to the Alzhei er’s Precision edicine Initiative ( P I) orking group [9], a blood-based bio arker of should provide a tool to assess subjects that are subjectively cognitively nor al or ith very early signs of cognitive decline in the primary care setting, allowing identification of the at-AD-risk subset who r…”
BackgroundMethodInfluentialAlzheimer's disease drug development pipeline: 2018
Cummings, J., Lee, G., Ritter, A., & Zhong, K. (2018) · Alzheimer's & Dementia: Translational Research & Clinical Interventions · doi:10.1016/j.trci.2018.03.009 · Cited by 697
Self-citationAlzheimer's disease drug development pipeline: 2017
Cummings, J., Lee, G., Mortsdorf, T., Ritter, A., & Zhong, K. (2017) · Alzheimer's & Dementia: Translational Research & Clinical Interventions · doi:10.1016/j.trci.2017.05.002 · Cited by 549 · cited 2×
“Among the contributing reasons for these failures is the absence of biomarkers for the early detection and the biological stratification of the participants in clinical studies [2].”
BackgroundSelf-citationAmnestic MCI or prodromal Alzheimer's disease?
Dubois, B., & Albert, M. L. (2004) · The Lancet Neurology · doi:10.1016/s1474-4422(04)00710-0 · Cited by 543
EFNS guidelines for the diagnosis and management of Alzheimer's disease
Hort, J., O’Brien, J. T., Gainotti, G., Pirttila, T., Popescu, B. O., Rektorova, I., Sorbi, S., Scheltens, P., & Dementia, O. B. O. T. E. S. P. O. (2010) · European Journal of Neurology · doi:10.1111/j.1468-1331.2010.03040.x · Cited by 490
Machine learning for comprehensive forecasting of Alzheimer’s Disease progression
Fisher, C. K., Smith, A. M., Walsh, J. R., Diseases, C. A. M., Simon, A. J., Edgar, C., Jack, C. R., Holtzman, D., Russell, D., Hill, D., et al. (2019) · Scientific Reports · doi:10.1038/s41598-019-49656-2 · Cited by 223
The role of tumor suppressor p53 in the antioxidant defense and metabolism
Budanov, A. V. (2014) · Subcellular Biochemistry · doi:10.1007/978-94-017-9211-0_18 · Cited by 157
Mitochondria and Cellular Redox State on the Route from Ageing to Alzheimer's Disease
Abate, G., Vezzoli, M., Sandri, M., Rungratanawanich, W., Memo, M., & Uberti, D. (2020) · Mechanisms of Ageing and Development · doi:10.1016/j.mad.2020.111385 · Cited by 41 · cited 1×
“Since p53 regulates a heterogeneous repertoire of biological functions [43,44], including neuronal outgrowth and neuronal connectivity protection [14,21], regulation of innate immunity [54], and redox homeostasis [21,55,56], we hypothesize that the expression of this conformational variant in the early stage of the di…”
BackgroundSelf-citationTramutola, A., Abate, G., Lanzillotta, C., Triani, F., Barone, E., Iavarone, F., Vincenzoni, F., Castagnola, M., Marziano, M., Memo, M., et al. (2018) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2018.10.414 · Cited by 26 · cited 1×
“It is now well established that clinical manifestations of AD are preceded by a long preclinical stage, during which pathophysiological processes might occur not only in the brain [3,4] but also at the periphery [5,6].”
BackgroundSelf-citation
Cited by
Machine Learning and Novel Biomarkers for the Diagnosis of Alzheimer’s Disease
Chang, C.-H., Lin, C.-H., & Lane, H.-Y. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22052761 · Cited by 257
Targeting Biomolecular Condensation and Protein Aggregation against Cancer
Silva, J. L., Foguel, D., Ferreira, V. F., Vieira, T. C. R. G., Marques, M. A., Ferretti, G. D. S., Outeiro, T. F., Cordeiro, Y., & de Oliveira, G. A. P. (2023) · Chemical Reviews · doi:10.1021/acs.chemrev.3c00131 · Cited by 89
Blanco, K., Salcidua, S., Orellana, P., Sauma-Pérez, T., León, T., Steinmetz, L. C. L., Ibañez, A., Duran-Aniotz, C., & de la Cruz, R. (2023) · Alzheimer's Research & Therapy · doi:10.1186/s13195-023-01304-8 · Cited by 73
Academic Skills in Children with Cerebral Palsy and Specific Learning Disorders
Micheletti, S., Galli, J., Vezzoli, M., Scaglioni, V., Agostini, S., Calza, S., Merabet, L. B., & Fazzi, E. (2024) · Developmental Medicine & Child Neurology · doi:10.1111/dmcn.15808 · Cited by 14
Self-citation
Metadata
- Authors
- Abate, G., Vezzoli, M., Polito, L., Guaita, A., Albani, D., Marizzoni, M., Garrafa, E., Marengoni, A., Forloni, G., Frisoni, G. B., Cummings, J. L., Memo, M., & Uberti, D.
- Venue
- Journal of Personalized Medicine
- Publisher
- MDPI AG
- Published
- 2020-12-26
- Volume
- 11
- Issue
- 1
- Pages
- 14
- ISSN
- 2075-4426 (ISSN-L)
- OpenAlex
- W3113755162
- Cited by
- 32
- References
- 16
- FWCI
- 3.51
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.